The risk of pain deterioration was similar with T-DXd/pertuzumab vs standard of care in the DESTINY-Breast09 trial.
Paige Britt
Advertisement
Articles by Paige Britt
Estrogen alone was associated with a lower risk of BRCA-mutated breast cancer, according to data from an ongoing study.
The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.
ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.
Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.
Advertisement
Latest Updated Articles
Durvalumab Combo Prolongs DFS in High-Risk BCG-Naive NMIBCOctober 17th 2025
PRO Data Support T-DXd Combo in HER2+ Advanced Breast CancerDecember 20th 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5